The Dr Burzynski problem, page-11

I still see a lot of potential in the medical imaging space, especially anything that can lead to an earlier diagnosis without the need to go under the knife unless it's absolutely necessary. Also correctly targeted imaging agents have the potential to be used as the basis for a treatment by adding a radioactive agent to the imaging agent. If TLX can have a 2 billion dollar market cap on only a single commercial imaging agent that has a smaller addressable market than the agent IBX is developing then I can see them following in their footsteps should they get to commercialisation. I am hedging my bets in this space and right now see RAD as the superior pipeline of the 2 companies but I can see both doing well long term in their own right if they can get their products to market